Product Details
Place of Origin: China
Document: Product Brochure PDF
Payment & Shipping Terms
Minimum Order Quantity: 10Grams
Price: USD
Packaging Details: 1kg/Foil Bag
Delivery Time: 3-7days after received payment
Payment Terms: T/T, Western Union,PayPal
Supply Ability: 5000KG Per Year
Product Name: |
Exemestane |
Cas: |
107868-30-4 |
Appearance: |
White Powder |
Purity: |
99% |
Usage: |
Anti-Cancer |
Product Name: |
Exemestane |
Cas: |
107868-30-4 |
Appearance: |
White Powder |
Purity: |
99% |
Usage: |
Anti-Cancer |
Exemestane Aromasin Raw Powder Cas 107868-30-4 For Anti-Cancer
Description
Exemestane chemical name is 1,4-diene-3,17-dione-6-methyleneandrostane or 6-methyleneandrostane-1,4-diene-3,17-dione , is white or off-white crystalline powder; odorless. Soluble in chloroform, soluble in ethyl acetate, methanol or ethanol, almost insoluble in water. It is clinically applicable to postmenopausal patients with advanced breast cancer whose disease has progressed after tamoxifen treatment.
The growth of breast cancer cells can be dependent on the presence of , circulating (estrone and estradiol) in postmenopausal women mainly by aromatase in peripheral tissues ketone and). Blocking production by inhibiting aromatase is an effective and selective treatment for postmenopausal hormone-dependent breast cancer.
Exemestane is an irreversible steroidal aromatase inactivator, which is similar in structure to the natural substrate of the enzyme androstenedione. It is inactivated by binding to dots (this effect is also called "self-destructive inhibition"), thereby significantly reducing the circulating levels in postmenopausal women, but has no significant effect on the biosynthesis of corticosteroids and aldosterol in the adrenal gland. When it is 600 times higher than the concentration of inhibiting aromatase, it has no obvious effect on other enzymes in the steroidogenic pathway.
Application
1. A second-generation aromatase inhibitor, used for the treatment of metastatic breast cancer and as an adjuvant therapy for early breast cancer.
2. Developed by Pharmacia&Upjohn Company. Approved by the US FDA in October 1997. Antineoplastic drug, second-generation aromatase inhibitor. Exemestane is the first oral hormone drug, which can be selectively targeted and permanently Combined with aromatase, once exemestane binds to the enzyme, the enzyme can never make again. It can inhibit the supply of to cancer cells and help prevent cells from continuing to grow. It is used to treat metastatic Breast cancer and its use as adjuvant therapy for early breast cancer.
3. This product is a second-generation aromatase inhibitor. It can irreversibly combine with aromatase to inactivate it, thereby preventing the biosynthesis of. It is clinically used to treat metastatic breast cancer and early breast cancer adjuvant therapy, with definite curative effect, good tolerance and relatively few side effects
FAQ:
